AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Cancer Education
Explore expert insights on the fundamentals of cancer, including how it develops, key risk factors, prevention strategies, and treatment options. This section also highlights cancer awareness months and related observance days and weeks. Commentaries from our network of oncology professionals shed light on critical issues that require greater attention across the cancer care and research continuum.
HIF-2 Alpha Inhibition in Kidney Cancer: From Adjuvant Belzutifan to the Post-Immunotherapy Setting
By Haris Zahoor, MD
HIF-2 alpha inhibition, first validated in metastatic clear cell renal cell carcinoma (RCC) with belzutifan, is now extending into new treatment settings.
HIF-2 Alpha Inhibition in Kidney Cancer: From Adjuvant Belzutifan to the Post-Immunotherapy Setting
By Haris Zahoor, MD
HIF-2 alpha inhibition, first validated in metastatic clear cell renal cell carcinoma (RCC) with belzutifan, is now extending into new treatment settings.
HIF-2 Alpha Inhibition in Kidney Cancer: From Adjuvant Belzutifan to the Post-Immunotherapy Setting
By Haris Zahoor, MD
HIF-2 alpha inhibition, first validated in metastatic clear cell renal cell carcinoma (RCC) with belzutifan, is now extending into new treatment settings.
Daraxonrasib and the RAS(ON) Revolution in Pancreatic Cancer Treatment
By Andrew H. Ko, MD
A new oral RAS(ON) inhibitor, daraxonrasib, nearly doubled overall survival compared with chemotherapy in patients with previously treated metastatic pancreatic cancer in the Phase 3 RASolute 302 trial.
Daraxonrasib and the RAS(ON) Revolution in Pancreatic Cancer Treatment
By Andrew H. Ko, MD
A new oral RAS(ON) inhibitor, daraxonrasib, nearly doubled overall survival compared with chemotherapy in patients with previously treated metastatic pancreatic cancer in the Phase 3 RASolute 302 trial.
Daraxonrasib and the RAS(ON) Revolution in Pancreatic Cancer Treatment
By Andrew H. Ko, MD
A new oral RAS(ON) inhibitor, daraxonrasib, nearly doubled overall survival compared with chemotherapy in patients with previously treated metastatic pancreatic cancer in the Phase 3 RASolute 302 trial.
How to Treat Mantle Cell Lymphoma in 2026
By Yucai Wang, MD, PhD
Frontline treatment for mantle cell lymphoma (MCL) is no longer a simple, one-size-fits-all algorithm split by transplant eligibility
How to Treat Mantle Cell Lymphoma in 2026
By Yucai Wang, MD, PhD
Frontline treatment for mantle cell lymphoma (MCL) is no longer a simple, one-size-fits-all algorithm split by transplant eligibility
How to Treat Mantle Cell Lymphoma in 2026
By Yucai Wang, MD, PhD
Frontline treatment for mantle cell lymphoma (MCL) is no longer a simple, one-size-fits-all algorithm split by transplant eligibility
The First Positive Phase 3 Trial Ever in Dedifferentiated Liposarcoma Changes a Difficult Conversation
By David Savage, MD
Dedifferentiated liposarcoma has had no positive phase 3 trial in its history, and existing chemotherapy options rarely delay progression beyond a few months.
The First Positive Phase 3 Trial Ever in Dedifferentiated Liposarcoma Changes a Difficult Conversation
By David Savage, MD
Dedifferentiated liposarcoma has had no positive phase 3 trial in its history, and existing chemotherapy options rarely delay progression beyond a few months.
The First Positive Phase 3 Trial Ever in Dedifferentiated Liposarcoma Changes a Difficult Conversation
By David Savage, MD
Dedifferentiated liposarcoma has had no positive phase 3 trial in its history, and existing chemotherapy options rarely delay progression beyond a few months.
Will Multispecific CAR T-Cell Therapy Replace Single-Target CD19 Treatment in Lymphoma?
By Saurabh Dahiya, MD, FACP
CD19-directed CAR T-cell therapy has transformed care for B-cell lymphomas, but most patients still relapse, often due to loss of the CD19 target.
Will Multispecific CAR T-Cell Therapy Replace Single-Target CD19 Treatment in Lymphoma?
By Saurabh Dahiya, MD, FACP
CD19-directed CAR T-cell therapy has transformed care for B-cell lymphomas, but most patients still relapse, often due to loss of the CD19 target.
Will Multispecific CAR T-Cell Therapy Replace Single-Target CD19 Treatment in Lymphoma?
By Saurabh Dahiya, MD, FACP
CD19-directed CAR T-cell therapy has transformed care for B-cell lymphomas, but most patients still relapse, often due to loss of the CD19 target.
KSHV-Associated Multicentric Castleman Disease: A Distinct Diagnosis With Distinct Treatment Considerations
By Kathryn Lurain, MD, MPH
KSHV/HHV8-associated multicentric Castleman disease (MCD) shares clinical features with idiopathic multicentric Castleman disease but has a distinct viral cause
KSHV-Associated Multicentric Castleman Disease: A Distinct Diagnosis With Distinct Treatment Considerations
By Kathryn Lurain, MD, MPH
KSHV/HHV8-associated multicentric Castleman disease (MCD) shares clinical features with idiopathic multicentric Castleman disease but has a distinct viral cause
KSHV-Associated Multicentric Castleman Disease: A Distinct Diagnosis With Distinct Treatment Considerations
By Kathryn Lurain, MD, MPH
KSHV/HHV8-associated multicentric Castleman disease (MCD) shares clinical features with idiopathic multicentric Castleman disease but has a distinct viral cause
Kidney Cancer Treatment Diversifies: Dual Immunotherapy, HIF-2α Inhibition, and TKI-Free Intervals
By Randy F. Sweis, MD
Frontline treatment of advanced renal cell carcinoma (RCC) now centers on a choice between dual immunotherapy and immunotherapy-TKI combinations, each with different tradeoffs in response rate versus durable remission.
Kidney Cancer Treatment Diversifies: Dual Immunotherapy, HIF-2α Inhibition, and TKI-Free Intervals
By Randy F. Sweis, MD
Frontline treatment of advanced renal cell carcinoma (RCC) now centers on a choice between dual immunotherapy and immunotherapy-TKI combinations, each with different tradeoffs in response rate versus durable remission.
Kidney Cancer Treatment Diversifies: Dual Immunotherapy, HIF-2α Inhibition, and TKI-Free Intervals
By Randy F. Sweis, MD
Frontline treatment of advanced renal cell carcinoma (RCC) now centers on a choice between dual immunotherapy and immunotherapy-TKI combinations, each with different tradeoffs in response rate versus durable remission.
Early-Stage Breast Cancer: Why Fewer Patients Need Chemotherapy, and More Need CDK4/6 Inhibitors
By Ruta Rao, MD
Genomic testing is increasingly identifying which early-stage, hormone receptor-positive breast cancer patients can safely skip chemotherapy, even among some node-positive premenopausal women.
Early-Stage Breast Cancer: Why Fewer Patients Need Chemotherapy, and More Need CDK4/6 Inhibitors
By Ruta Rao, MD
Genomic testing is increasingly identifying which early-stage, hormone receptor-positive breast cancer patients can safely skip chemotherapy, even among some node-positive premenopausal women.
Early-Stage Breast Cancer: Why Fewer Patients Need Chemotherapy, and More Need CDK4/6 Inhibitors
By Ruta Rao, MD
Genomic testing is increasingly identifying which early-stage, hormone receptor-positive breast cancer patients can safely skip chemotherapy, even among some node-positive premenopausal women.
Beyond G12C: KRAS Lung Cancer Is About to Become a Toolkit, Not a Single Target
By Benjamin Herzberg, MD
KRAS G12C is not the only KRAS mutation worth worrying about, and I think that idea is very close to being obsolete.
Beyond G12C: KRAS Lung Cancer Is About to Become a Toolkit, Not a Single Target
By Benjamin Herzberg, MD
KRAS G12C is not the only KRAS mutation worth worrying about, and I think that idea is very close to being obsolete.
Beyond G12C: KRAS Lung Cancer Is About to Become a Toolkit, Not a Single Target
By Benjamin Herzberg, MD
KRAS G12C is not the only KRAS mutation worth worrying about, and I think that idea is very close to being obsolete.
AL Amyloidosis, POEMS Syndrome, and Extramedullary Myeloma: Diagnosis Lags, Treatment Options Grow
By Jack Khouri, MD
AL amyloidosis remains a frequently missed, "sneaky" diagnosis, but the treatment landscape is genuinely transforming
AL Amyloidosis, POEMS Syndrome, and Extramedullary Myeloma: Diagnosis Lags, Treatment Options Grow
By Jack Khouri, MD
AL amyloidosis remains a frequently missed, "sneaky" diagnosis, but the treatment landscape is genuinely transforming
AL Amyloidosis, POEMS Syndrome, and Extramedullary Myeloma: Diagnosis Lags, Treatment Options Grow
By Jack Khouri, MD
AL amyloidosis remains a frequently missed, "sneaky" diagnosis, but the treatment landscape is genuinely transforming